Human immunodeficiency virus
InPheno’s team possesses several decades of expertise on the human immunodeficiency virus (HIV) and with profiling new candidate drugs for this key pathogen. Since its inception, InPheno has been assembling a precious collection of essential tools to meet the complexity of discovery and development of antiretroviral agents. Data and profiling reports generated by InPheno have passed the scrutiny of our customers and that of regulatory authorities for clinical testing in humans.
This record of accomplishment is the basis for us at InPheno to offer our services for meeting your needs in anti-HIV drug discovery.
InPheno has expanded its profiling portfolio to hepatitis B and C viruses. InPheno offers state of the art and well-established assays to identify and biologically profile the activity of compounds inhibiting these viruses.
With the global increase in the population at risk (e.g., elderly, immunocompromised patients), InPheno recognises the need to develop new drugs to fight off viral pneumonia. Therefore, InPheno has recently added to its line of products assays targeting the main agents causing viral pneumonia namely, influenza, respiratory syncytial virus (RSV) and parainfluenza virus (PIV).
HERPES SIMPLEX VIRUS
Building on the successful introduction of its new lines of product, InPheno now offers assays to identify and biologically profile the activity of compounds inhibiting Herpes simplex virus.